MIF and primary cutaneous T-cell non-Hodgkin lymphoma: As vorinostat, that is approved for the treatment of Cutaneous T Cell Lymphoma (CTCL) since 2006, has been shown to inhibit MIF production we wondered whether the in vitro chemotherapeutic action of this drug in MYCN transformed NB cell lines could be associated to down-modulation of MIF and DDT [66].